Role of hepatotropic viruses in promoting hepatocellular carcinoma—current knowledge and recent advances (original) (raw)

• Bray F, Ferlay J, Soerjomataram I, Siegel RL, Torre LA, Jemal A. Global cancer statistics 2018: GLOBOCAN estimates of incidence and mortality worldwide for 36 cancers in 185 countries. CA Cancer J Clin. 2018;68:394–424. https://doi.org/10.3322/caac.21492.
  Article PubMed Google Scholar
• Global, regional, and national burden of primary liver cancer by subtype . [cited 2025 Jan 8]. https://www.iarc.who.int/news-events/global-regional-and-national-burden-of-primary-liver-cancer-by-subtype/
• Singal AG, Lampertico P, Nahon P. Epidemiology and surveillance for hepatocellular carcinoma: New trends. J Hepatol. 2020;72:250–61. https://doi.org/10.1016/j.jhep.2019.08.025.
  Article CAS PubMed PubMed Central Google Scholar
• Jiang D, Zhang L, Liu W, Ding Y, Yin J, Ren R, et al. Trends in cancer mortality in China from 2004 to 2018: A nationwide longitudinal study. Cancer Commun (Lond). 2021;41:1024–36. https://doi.org/10.1002/cac2.12195.
  Article PubMed Google Scholar
• Llovet JM, Kelley RK, Villanueva A, Singal AG, Pikarsky E, Roayaie S, et al. Hepatocellular carcinoma Nat Rev Dis Primers. 2021;7:6. https://doi.org/10.1038/s41572-020-00240-3.
  Article PubMed Google Scholar
• Dhanasekaran R, Nault J-C, Roberts LR, Zucman-Rossi J. Genomic medicine and implications for hepatocellular carcinoma prevention and therapy. Gastroenterology. 2019;156:492–509. https://doi.org/10.1053/j.gastro.2018.11.001.
  Article CAS PubMed Google Scholar
• McGlynn KA, Petrick JL, El-Serag HB. Epidemiology of hepatocellular carcinoma. Hepatology. 2021;73(Suppl 1):4–13. https://doi.org/10.1002/hep.31288.
  Article CAS PubMed Google Scholar
• El-Serag HB, Rudolph KL. Hepatocellular carcinoma: epidemiology and molecular carcinogenesis. Gastroenterology. 2007;132:2557–76. https://doi.org/10.1053/j.gastro.2007.04.061.
  Article CAS PubMed Google Scholar
• Dobrowolska K, Brzdęk M, Rzymski P, Flisiak R, Pawłowska M, Janczura J, et al. Revolutionizing hepatitis C treatment: next-gen direct-acting antivirals. Expert Opin Pharmacother. 2024;25:833–52. https://doi.org/10.1080/14656566.2024.2358139.
  Article CAS PubMed Google Scholar
• Fiehn F, Beisel C, Binder M. Hepatitis C virus and hepatocellular carcinoma: carcinogenesis in the era of direct-acting antivirals. Curr Opin Virol. 2024;67: 101423. https://doi.org/10.1016/j.coviro.2024.101423.
  Article CAS PubMed Google Scholar
• Kanwal F, Kramer J, Asch SM, Chayanupatkul M, Cao Y, El-Serag HB. Risk of hepatocellular cancer in HCV patients treated with direct-acting antiviral agents. Gastroenterology. 2017;153:996-1005.e1. https://doi.org/10.1053/j.gastro.2017.06.012.
  Article CAS PubMed Google Scholar
• Kruse RL, Kramer JR, Tyson GL, Duan Z, Chen L, El-Serag HB, et al. Clinical outcomes of hepatitis B virus coinfection in a United States cohort of hepatitis C virus-infected patients. Hepatology. 2014;60:1871–8. https://doi.org/10.1002/hep.27337.
  Article PubMed Google Scholar
• Ioannou GN, Bryson CL, Weiss NS, Miller R, Scott JD, Boyko EJ. The prevalence of cirrhosis and hepatocellular carcinoma in patients with human immunodeficiency virus infection. Hepatology. 2013;57:249–57. https://doi.org/10.1002/hep.25800.
  Article PubMed Google Scholar
• Tseng T-C, Liu C-J, Chang CT, Su T-H, Yang W-T, Tsai C-H, et al. HEV superinfection accelerates disease progression in patients with chronic HBV infection and increases mortality in those with cirrhosis. J Hepatol. 2020;72:1105–11. https://doi.org/10.1016/j.jhep.2020.01.012.
  Article CAS PubMed Google Scholar
• Ninio L, Nissani A, Meirson T, Domovitz T, Genna A, Twafra S, et al. Hepatitis C virus enhances the invasiveness of hepatocellular carcinoma via EGFR-mediated invadopodia formation and activation. Cells. 2019;8:1395. https://doi.org/10.3390/cells8111395.
  Article CAS PubMed PubMed Central Google Scholar
• Galle PR, Forner A, Llovet JM, Mazzaferro V, Piscaglia F, Raoul J-L, et al. EASL Clinical Practice Guidelines: Management of hepatocellular carcinoma. J Hepatol. 2018;69:182–236. https://doi.org/10.1016/j.jhep.2018.03.019.
  Article Google Scholar
• Petruzziello A. Epidemiology of Hepatitis B Virus (HBV) and Hepatitis C Virus (HCV) related hepatocellular carcinoma. Open Virol J. 2018;12:26–32. https://doi.org/10.2174/1874357901812010026.
  Article CAS PubMed PubMed Central Google Scholar
• Kim DY. Changing etiology and epidemiology of hepatocellular carcinoma: Asia and worldwide. J Liver Canc . 2024;24:62–70. https://doi.org/10.17998/jlc.2024.03.13
• Shen C, Jiang X, Li M, Luo Y. Hepatitis virus and hepatocellular carcinoma: Recent advances. Cancers (Basel). 2023;15:533. https://doi.org/10.3390/cancers15020533.
  Article CAS PubMed Google Scholar
• Wenndt A, Mutua F, Grace D, Thomas LF, Lambertini E. Quantitative assessment of aflatoxin exposure and hepatocellular carcinoma (HCC) risk associated with consumption of select Nigerian staple foods. Front Sustain Food Syst . 2023;7. https://doi.org/10.3389/fsufs.2023.1128540
• Ashtari S, Pourhoseingholi MA, Sharifian A, Zali MR. Hepatocellular carcinoma in Asia: Prevention strategy and planning. World J Hepatol. 2015;7:1708–17. https://doi.org/10.4254/wjh.v7.i12.1708.
  Article PubMed PubMed Central Google Scholar
• Cardoso MF, Machado MV. The changing face of hepatitis delta virus associated hepatocellular carcinoma. Cancers (Basel) . 2024;16. https://doi.org/10.3390/cancers16223723
• Oyunsuren T, Kurbanov F, Tanaka Y, Elkady A, Sanduijav R, Khajidsuren O, et al. High frequency of hepatocellular carcinoma in Mongolia; association with mono-, or co-infection with hepatitis C, B, and delta viruses. J Med Virol. 2006;78:1688–95. https://doi.org/10.1002/jmv.20755.
  Article CAS PubMed Google Scholar
• Axley P, Ahmed Z, Ravi S, Singal AK. Hepatitis C virus and hepatocellular carcinoma: A narrative review. J Clin Transl Hepatol . 2018;6:79–84. https://doi.org/10.14218/JCTH.2017.00067
• Taniai M. Alcohol and hepatocarcinogenesis Clin Mol Hepatol. 2020;26:736–41. https://doi.org/10.3350/cmh.2020.0203.
  Article PubMed Google Scholar
• Matsushita H, Takaki A. Alcohol and hepatocellular carcinoma. BMJ Open Gastroenterol. 2019;6: e000260. https://doi.org/10.1136/bmjgast-2018-000260.
  Article PubMed PubMed Central Google Scholar
• Ramadori P, Cubero F, Liedtke C, Trautwein C, Nevzorova Y. Alcohol and hepatocellular carcinoma: Adding fuel to the flame. Cancers (Basel). 2017;9:130. https://doi.org/10.3390/cancers9100130.
  Article CAS PubMed Google Scholar
• Huang DQ, Tan DJH, Ng CH, Amangurbanova M, Sutter N, Lin Tay PW, et al. Hepatocellular carcinoma incidence in alcohol-associated cirrhosis: Systematic review and meta-analysis. Clin Gastroenterol Hepatol. 2023;21:1169–77. https://doi.org/10.1016/j.cgh.2022.06.032.
  Article CAS PubMed Google Scholar
• Kew MC. Obesity as a cause of hepatocellular carcinoma. Ann Hepatol. 2015;14:299–303. https://doi.org/10.1016/s1665-2681(19)31267-0.
  Article CAS PubMed Google Scholar
• Siegel AB, Zhu AX. Metabolic syndrome and hepatocellular carcinoma: two growing epidemics with a potential link. Cancer. 2009;115:5651–61. https://doi.org/10.1002/cncr.24687.
  Article PubMed Google Scholar
• Agosti P, Sabbà C, Mazzocca A. Emerging metabolic risk factors in hepatocellular carcinoma and their influence on the liver microenvironment. Biochim Biophys Acta Mol Basis Dis. 2018;1864:607–17. https://doi.org/10.1016/j.bbadis.2017.11.026.
  Article CAS PubMed Google Scholar
• Turati F, Talamini R, Pelucchi C, Polesel J, Franceschi S, Crispo A, et al. Metabolic syndrome and hepatocellular carcinoma risk. Br J Cancer. 2013;108:222–8. https://doi.org/10.1038/bjc.2012.492.
  Article CAS PubMed Google Scholar
• Janota B, Szymanek B. The influence of diet and its components on the development and prevention of hepatocellular carcinoma (HCC). Cancers (Basel). 2024;16:1030. https://doi.org/10.3390/cancers16051030.
  Article CAS PubMed Google Scholar
• Wu H-C, Wang Q, Yang H-I, Ahsan H, Tsai W-Y, Wang L-Y, et al. Aflatoxin B1 exposure, hepatitis B virus infection, and hepatocellular carcinoma in Taiwan. Cancer Epidemiol Biomarkers Prev. 2009;18:846–53. https://doi.org/10.1158/1055-9965.EPI-08-0697.
  Article CAS PubMed PubMed Central Google Scholar
• Wang W, Wei C. Advances in the early diagnosis of hepatocellular carcinoma. Genes Dis. 2020;7:308–19. https://doi.org/10.1016/j.gendis.2020.01.014.
  Article CAS PubMed PubMed Central Google Scholar
• Miki D, Ochi H, Hayes CN, Abe H, Yoshima T, Aikata H, et al. Variation in the DEPDC5 locus is associated with progression to hepatocellular carcinoma in chronic hepatitis C virus carriers. Nat Genet. 2011;43:797–800. https://doi.org/10.1038/ng.876.
  Article CAS PubMed Google Scholar
• Zarembska E, Ślusarczyk K, Wrzosek M. The implication of a polymorphism in the methylenetetrahydrofolate reductase gene in homocysteine metabolism and related civilisation diseases. Int J Mol Sci . 2023;25. https://doi.org/10.3390/ijms25010193
• Muto S, Enta A, Maruya Y, Inomata S, Yamaguchi H, Mine H, et al. Wnt/β-catenin signaling and resistance to immune checkpoint inhibitors: From non-small-cell lung cancer to other cancers. Biomedicines. 2023;11:190. https://doi.org/10.3390/biomedicines11010190.
  Article CAS PubMed PubMed Central Google Scholar
• Chan TA, Yarchoan M, Jaffee E, Swanton C, Quezada SA, Stenzinger A, et al. Development of tumor mutation burden as an immunotherapy biomarker: utility for the oncology clinic. Ann Oncol. 2019;30:44–56. https://doi.org/10.1093/annonc/mdy495.
  Article CAS PubMed Google Scholar
• Zheng J, Wang S, Xia L, Sun Z, Chan KM, Bernards R, et al. Hepatocellular carcinoma: signaling pathways and therapeutic advances. Signal Transduct Target Ther. 2025;10:35. https://doi.org/10.1038/s41392-024-02075-w.
  Article PubMed PubMed Central Google Scholar
• Xu Y, Cai J, Zhong K, Wen Y, Cai L, He G, et al. Plasma-only circulating tumor DNA analysis detects minimal residual disease and predicts early relapse in hepatocellular carcinoma patients undergoing curative resection. Front Oncol. 2023;13:1119744. https://doi.org/10.3389/fonc.2023.1119744.
  Article CAS PubMed PubMed Central Google Scholar
• Cabral LKD, Tiribelli C, Sukowati CHC. Sorafenib resistance in hepatocellular carcinoma: The relevance of genetic heterogeneity. Cancers (Basel). 2020;12:1576. https://doi.org/10.3390/cancers12061576.
  Article CAS PubMed Google Scholar
• Wang Y, Deng B. Hepatocellular carcinoma: molecular mechanism, targeted therapy, and biomarkers. Cancer Metastasis Rev. 2023;42:629–52. https://doi.org/10.1007/s10555-023-10084-4.
  Article PubMed Google Scholar
• Wei Y-G, Liu F, Li B, Chen X, Ma Y, Yan L-N, et al. Interleukin-10 gene polymorphisms and hepatocellular carcinoma susceptibility: a meta-analysis. World J Gastroenterol. 2011;17:3941–7. https://doi.org/10.3748/wjg.v17.i34.3941.
  Article CAS PubMed PubMed Central Google Scholar
• Heredia-Torres TG, Rincón-Sánchez AR, Lozano-Sepúlveda SA, Galan-Huerta K, Arellanos-Soto D, García-Hernández M, et al. Unraveling the molecular mechanisms involved in HCV-induced carcinogenesis. Viruses. 2022;14:2762. https://doi.org/10.3390/v14122762.
  Article CAS PubMed PubMed Central Google Scholar
• Lopez-Scarim J, Nambiar SM, Billerbeck E. Studying T cell responses to hepatotropic viruses in the liver microenvironment. Vaccines (Basel) . 2023;11. https://doi.org/10.3390/vaccines11030681
• Chuang Y-C, Tsai K-N, Ou J-HJ. Pathogenicity and virulence of Hepatitis B virus. Virulence . 2022;13:258–96. https://doi.org/10.1080/21505594.2022.2028483
• Iannacone M, Guidotti LG. Immunobiology and pathogenesis of hepatitis B virus infection. Nat Rev Immunol. 2022;22:19–32. https://doi.org/10.1038/s41577-021-00549-4.
  Article CAS PubMed Google Scholar
• Diaz O, Vidalain P-O, Ramière C, Lotteau V, Perrin-Cocon L. What role for cellular metabolism in the control of hepatitis viruses? Front Immunol. 2022;13:1033314. https://doi.org/10.3389/fimmu.2022.1033314.
  Article CAS PubMed PubMed Central Google Scholar
• Li J, Wang Y, Deng H, Li S, Qiu H-J. Cellular metabolism hijacked by viruses for immunoevasion: potential antiviral targets. Front Immunol. 2023;14:1228811. https://doi.org/10.3389/fimmu.2023.1228811.
  Article CAS PubMed PubMed Central Google Scholar
• Selvamani SP, Khan A, Tay ESE, Garvey M, Ajoyan H, Diefenbach E, et al. Hepatitis B virus and hepatitis C virus affect mitochondrial function through different metabolic pathways, explaining virus-specific clinical features of chronic hepatitis. J Infect Dis. 2024;230:e1012–22. https://doi.org/10.1093/infdis/jiae210.
  Article CAS PubMed PubMed Central Google Scholar
• Gerresheim GK, Roeb E, Michel AM, Niepmann M. Hepatitis C virus downregulates core subunits of oxidative phosphorylation, reminiscent of the Warburg Effect in cancer cells. Cells. 2019;8:1410. https://doi.org/10.3390/cells8111410.
  Article CAS PubMed PubMed Central Google Scholar
• Gnocchi D, Kurzyk A, Mintrone A, Lentini G, Sabbà C, Mazzocca A. Inhibition of LPAR6 overcomes sorafenib resistance by switching glycolysis into oxidative phosphorylation in hepatocellular carcinoma. Biochimie. 2022;202:180–9. https://doi.org/10.1016/j.biochi.2022.07.016.
  Article CAS PubMed Google Scholar
• Sivasudhan E, Blake N, Lu Z, Meng J, Rong R. Hepatitis B viral protein HBx and the molecular mechanisms modulating the hallmarks of hepatocellular carcinoma: A comprehensive review. Cells. 2022;11:741. https://doi.org/10.3390/cells11040741.
  Article CAS PubMed PubMed Central Google Scholar
• Wazir H, Abid M, Essani B, Saeed H, Ahmad Khan M, Nasrullah F, et al. Diagnosis and treatment of liver disease: Current trends and future directions. Cureus. 2023;15: e49920. https://doi.org/10.7759/cureus.49920.
  Article PubMed PubMed Central Google Scholar
• Chan Y-T, Zhang C, Wu J, Lu P, Xu L, Yuan H, et al. Biomarkers for diagnosis and therapeutic options in hepatocellular carcinoma. Mol Cancer. 2024;23:189. https://doi.org/10.1186/s12943-024-02101-z.
  Article PubMed PubMed Central Google Scholar
• Singal AG, Llovet JM, Yarchoan M, Mehta N, Heimbach JK, Dawson LA, et al. AASLD Practice Guidance on prevention, diagnosis, and treatment of hepatocellular carcinoma. Hepatology. 2023;78:1922–65. https://doi.org/10.1097/HEP.0000000000000466.
  Article PubMed Google Scholar
• Attia AM, Rezaee-Zavareh MS, Hwang SY, Kim N, Adetyan H, Yalda T, et al. Novel biomarkers for early detection of hepatocellular carcinoma. Diagnostics (Basel). 2024;14:2278. https://doi.org/10.3390/diagnostics14202278.
  Article CAS PubMed Google Scholar
• Li B, Hao K, Li M, Wang A, Tang H, Xu L, et al. Five miRNAs identified in fucosylated extracellular vesicles as non-invasive diagnostic signatures for hepatocellular carcinoma. Cell Rep Med. 2024;5: 101716. https://doi.org/10.1016/j.xcrm.2024.101716.
  Article CAS PubMed PubMed Central Google Scholar
• Guo D-Z, Huang A, Wang Y-C, Zhou S, Wang H, Xing X-L, et al. Early detection and prognosis evaluation for hepatocellular carcinoma by circulating tumour DNA methylation: A multicentre cohort study. Clin Transl Med. 2024;14: e1652. https://doi.org/10.1002/ctm2.1652.
  Article CAS PubMed PubMed Central Google Scholar
• Li X, Corbett AL, Taatizadeh E, Tasnim N, Little JP, Garnis C, et al. Challenges and opportunities in exosome research-Perspectives from biology, engineering, and cancer therapy. APL Bioeng. 2019;3: 011503. https://doi.org/10.1063/1.5087122.
  Article CAS PubMed PubMed Central Google Scholar
• Lampertico P, Agarwal K, Berg T, Buti M, Janssen HLA, Papatheodoridis G, et al. EASL 2017 Clinical Practice Guidelines on the management of hepatitis B virus infection. J Hepatol. 2017;67:370–98. https://doi.org/10.1016/j.jhep.2017.03.021.
  Article Google Scholar
• Lin C-Y, Sun W-C, Lu C-M, Chen W-C, Tsay F-W, Tsai T-J, et al. Entecavir vs. tenofovir disoproxil fumarate in the treatment of chronic hepatitis B patients with severe acute exacerbation. Eur J Gastroenterol Hepatol . 2024;36:1113–8. https://doi.org/10.1097/MEG.0000000000002709
• Choi W-M, Yip TC-F, Wong GL-H, Kim WR, Yee LJ, Brooks-Rooney C, et al. Hepatocellular carcinoma risk in patients with chronic hepatitis B receiving tenofovir- vs. entecavir-based regimens: Individual patient data meta-analysis. J Hepatol . 2023;78:534–42. https://doi.org/10.1016/j.jhep.2022.12.007
• Choi J, Kim HJ, Lee J, Cho S, Ko MJ, Lim Y-S. Risk of hepatocellular carcinoma in patients treated with entecavir vs tenofovir for chronic hepatitis B: A Korean nationwide cohort study. JAMA Oncol. 2019;5:30–6. https://doi.org/10.1001/jamaoncol.2018.4070.
  Article PubMed Google Scholar
• Tan DJH, Ng CH, Tay PWL, Syn N, Muthiah MD, Lim WH, et al. Risk of hepatocellular carcinoma with tenofovir vs entecavir treatment for chronic hepatitis B virus: A reconstructed individual patient data meta-analysis. JAMA Netw Open. 2022;5: e2219407. https://doi.org/10.1001/jamanetworkopen.2022.19407.
  Article PubMed PubMed Central Google Scholar
• Su F, Berry K, Ioannou GN. No difference in hepatocellular carcinoma risk between chronic hepatitis B patients treated with entecavir versus tenofovir. Gut. 2021;70:370–8. https://doi.org/10.1136/gutjnl-2019-319867.
  Article CAS PubMed Google Scholar
• Zając M, Muszalska I, Sobczak A, Dadej A, Tomczak S, Jelińska A. Hepatitis C - New drugs and treatment prospects. Eur J Med Chem. 2019;165:225–49. https://doi.org/10.1016/j.ejmech.2019.01.025.
  Article CAS PubMed Google Scholar
• Singal AK, Singh A, Jaganmohan S, Guturu P, Mummadi R, Kuo Y-F, et al. Antiviral therapy reduces risk of hepatocellular carcinoma in patients with hepatitis C virus-related cirrhosis. Clin Gastroenterol Hepatol. 2010;8:192–9. https://doi.org/10.1016/j.cgh.2009.10.026.
  Article PubMed Google Scholar
• van der Meer AJ, Veldt BJ, Feld JJ, Wedemeyer H, Dufour J-F, Lammert F, et al. Association between sustained virological response and all-cause mortality among patients with chronic hepatitis C and advanced hepatic fibrosis. JAMA. 2012;308:2584–93. https://doi.org/10.1001/jama.2012.144878.
  Article PubMed Google Scholar
• Ioannou GN, Green PK, Berry K. HCV eradication induced by direct-acting antiviral agents reduces the risk of hepatocellular carcinoma. J Hepatol. 2017;68:25–32. https://doi.org/10.1016/j.jhep.2017.08.030.
  Article Google Scholar
• Conti F, Buonfiglioli F, Scuteri A, Crespi C, Bolondi L, Caraceni P, et al. Early occurrence and recurrence of hepatocellular carcinoma in HCV-related cirrhosis treated with direct-acting antivirals. J Hepatol. 2016;65:727–33. https://doi.org/10.1016/j.jhep.2016.06.015.
  Article CAS PubMed Google Scholar
• Singer AW, Reddy KR, Telep LE, Osinusi AO, Brainard DM, Buti M, et al. Direct-acting antiviral treatment for hepatitis C virus infection and risk of incident liver cancer: a retrospective cohort study. Aliment Pharmacol Ther. 2018;47:1278–87. https://doi.org/10.1111/apt.14593.
  Article CAS PubMed Google Scholar
• Reig M, Mariño Z, Perelló C, Iñarrairaegui M, Ribeiro A, Lens S, et al. Unexpected high rate of early tumor recurrence in patients with HCV-related HCC undergoing interferon-free therapy. J Hepatol. 2016;65:719–26. https://doi.org/10.1016/j.jhep.2016.04.008.
  Article CAS PubMed Google Scholar
• Frazzoni L, Sikandar U, Metelli F, Sadalla S, Mazzella G, Bazzoli F, et al. Hepatocellular carcinoma recurrence after hepatitis C virus therapy with direct-acting antivirals. A systematic review and meta-analysis. J Clin Med . 2021;10:1694. https://doi.org/10.3390/jcm10081694
• Ravi S, Axley P, Jones D, Kodali S, Simpson H, McGuire BM, et al. Unusually high rates of hepatocellular carcinoma after treatment with direct-acting antiviral therapy for hepatitis C related cirrhosis. Gastroenterology. 2017;152:911–2. https://doi.org/10.1053/j.gastro.2016.12.021.
  Article PubMed Google Scholar
• Li L, Wang H. Heterogeneity of liver cancer and personalized therapy. Cancer Lett. 2016;379:191–7. https://doi.org/10.1016/j.canlet.2015.07.018.
  Article CAS PubMed Google Scholar
• Harkus U, Wankell M, Palamuthusingam P, McFarlane C, Hebbard L. Immune checkpoint inhibitors in HCC: Cellular, molecular and systemic data. Semin Cancer Biol. 2022;86:799–815. https://doi.org/10.1016/j.semcancer.2022.01.005.
  Article CAS PubMed Google Scholar
• Anwar J, Arslan HM, Sarfraz Z, Shuroog J, Abdelhakeem A, Saeed A, et al. Immunotherapy responses in viral hepatitis-induced HCC: A systematic review and meta-analysis. Curr Oncol. 2024;31:7204–25. https://doi.org/10.3390/curroncol31110532.
  Article PubMed PubMed Central Google Scholar
• Tan AT, Bertoletti A. HBV-HCC treatment with mRNA electroporated HBV-TCR T cells. Immunother Adv . 2022;2:ltab026. https://doi.org/10.1093/immadv/ltab026
• Cai B, Chang S, Tian Y, Zhen S. CRISPR/Cas9 for hepatitis B virus infection treatment. Immun Inflamm Dis. 2023;11: e866. https://doi.org/10.1002/iid3.866.
  Article CAS PubMed PubMed Central Google Scholar
• Zoulim F, Lenz O, Vandenbossche JJ, Talloen W, Verbinnen T, Moscalu I, et al. JNJ-56136379, an HBV capsid assembly modulator, is well-tolerated and has antiviral activity in a phase 1 study of patients with chronic infection. Gastroenterology. 2020;159:521-533.e9. https://doi.org/10.1053/j.gastro.2020.04.036.
  Article CAS PubMed Google Scholar
• Llovet JM, Castet F, Heikenwalder M, Maini MK, Mazzaferro V, Pinato DJ, et al. Immunotherapies for hepatocellular carcinoma. Nat Rev Clin Oncol. 2022;19:151–72. https://doi.org/10.1038/s41571-021-00573-2.
  Article CAS PubMed Google Scholar
• Kudo M, Ueshima K, Nakahira S, Nishida N, Ida H, Minami Y, et al. Final results of adjuvant nivolumab for hepatocellular carcinoma (HCC) after surgical resection (SR) or radiofrequency ablation (RFA) (NIVOLVE): A phase 2 prospective multicenter single-arm trial and exploratory biomarker analysis. J Clin Oncol. 2022;40:416–416. https://doi.org/10.1200/jco.2022.40.4_suppl.416.
  Article Google Scholar
• Gaudel P, Mohyuddin GR, Fields-Meehan J. Nivolumab use for first-line management of hepatocellular carcinoma: Results of a real-world cohort of patients. Fed Pract. 2021;38:89–91. https://doi.org/10.12788/fp.0061.
  Article PubMed PubMed Central Google Scholar
• Pinter M, Scheiner B, Pinato DJ. Immune checkpoint inhibitors in hepatocellular carcinoma: emerging challenges in clinical practice. Lancet Gastroenterol Hepatol. 2023;8:760–70. https://doi.org/10.1016/S2468-1253(23)00147-4.
  Article CAS PubMed Google Scholar
• Finn RS, Ryoo B-Y, Merle P, Kudo M, Bouattour M, Lim HY, et al. Pembrolizumab as second-line therapy in patients with advanced hepatocellular carcinoma in KEYNOTE-240: A randomized, double-blind, phase III trial. J Clin Oncol. 2020;38:193–202. https://doi.org/10.1200/JCO.19.01307.
  Article CAS PubMed Google Scholar
• Qin S, Chen Z, Fang W, Ren Z, Xu R, Ryoo B-Y, et al. Pembrolizumab versus placebo as second-line therapy in patients from Asia with advanced hepatocellular carcinoma: A randomized, double-blind, phase III trial. J Clin Oncol. 2023;41:1434–43. https://doi.org/10.1200/JCO.22.00620.
  Article CAS PubMed Google Scholar
• Finn RS, Qin S, Ikeda M, Galle PR, Ducreux M, Kim T-Y, et al. Atezolizumab plus bevacizumab in unresectable hepatocellular carcinoma. N Engl J Med. 2020;382:1894–905. https://doi.org/10.1056/NEJMoa1915745.
  Article CAS PubMed Google Scholar
• Jost-Brinkmann F, Demir M, Wree A, Luedde T, Loosen SH, Müller T, et al. Atezolizumab plus bevacizumab in unresectable hepatocellular carcinoma: Results from a German real-world cohort. Aliment Pharmacol Ther. 2023;57:1313–25. https://doi.org/10.1111/apt.17441.
  Article CAS PubMed Google Scholar
• Ding Z, Dong Z, Chen Z, Hong J, Yan L, Li H, et al. Viral status and efficacy of immunotherapy in hepatocellular carcinoma: A systematic review with meta-analysis. Front Immunol. 2021;12: 733530. https://doi.org/10.3389/fimmu.2021.733530.
  Article CAS PubMed PubMed Central Google Scholar
• Gnocchi D, Sabbà C, Massimi M, Mazzocca A. Metabolism as a new avenue for hepatocellular carcinoma therapy. Int J Mol Sci . 2023;24. https://doi.org/10.3390/ijms24043710
• Chiang C-J, Yang Y-W, You S-L, Lai M-S, Chen C-J. Thirty-year outcomes of the national hepatitis B immunization program in Taiwan. JAMA. 2013;310:974–6. https://doi.org/10.1001/jama.2013.276701.
  Article CAS PubMed Google Scholar
• Hepatitis B . [cited 2024 Dec 4]. https://www.who.int/news-room/fact-sheets/detail/hepatitis-b
• Alexopoulou A, Vasilieva L, Karayiannis P. New approaches to the treatment of chronic hepatitis B. J Clin Med. 2020;9:3187. https://doi.org/10.3390/jcm9103187.
  Article CAS PubMed PubMed Central Google Scholar
• Karnsakul W, Schwarz KB. Hepatitis B and C. Pediatr Clin North Am. 2017;64:641–58. https://doi.org/10.1016/j.pcl.2017.01.007.
  Article PubMed PubMed Central Google Scholar
• Flores JE, Thompson AJ, Ryan M, Howell J. The global impact of hepatitis B vaccination on hepatocellular carcinoma. Vaccines (Basel). 2022;10:793. https://doi.org/10.3390/vaccines10050793.
  Article PubMed Google Scholar
• Kaya E, Daniel Mazzolini G, Yilmaz Y, Canbay A. Prevention of hepatocellular carcinoma and monitoring of high-risk patients. Hepatol Forum . 2022;3:33–8. https://doi.org/10.14744/hf.2021.2021.0033
• Onyirioha K, Mittal S, Singal G, A. Is hepatocellular carcinoma surveillance in high-risk populations effective? Hepat Oncol. 2020;7:HEP25. https://doi.org/10.2217/hep-2020-0012.
  Article PubMed PubMed Central Google Scholar
• Singal AG, Pillai A, Tiro J. Early detection, curative treatment, and survival rates for hepatocellular carcinoma surveillance in patients with cirrhosis: a meta-analysis. PLoS Med. 2014;11:e1001624. https://doi.org/10.1371/journal.pmed.1001624.
  Article PubMed PubMed Central Google Scholar
• Feng G-H, Zhao K-H, Wang Y-F, Yue Q-Q, Chen Y-S, Huang L-L, et al. Mhealth-based interventions to improving liver cancer screening among high-risk populations: A study protocol for a randomized controlled trial. BMC Public Health. 2024;24:2501. https://doi.org/10.1186/s12889-024-20025-7.
  Article PubMed PubMed Central Google Scholar
• Allaire M, Bruix J, Korenjak M, Manes S, Maravic Z, Reeves H, et al. What to do about hepatocellular carcinoma: Recommendations for health authorities from the International Liver Cancer Association. JHEP Rep. 2022;4:100578. https://doi.org/10.1016/j.jhepr.2022.100578.
  Article PubMed PubMed Central Google Scholar
• Addissouky TA, Sayed IETE, Ali MMA, Wang Y, Baz AE, Khalil AA, et al. Latest advances in hepatocellular carcinoma management and prevention through advanced technologies. Egypt Liver J. 2024. https://doi.org/10.1186/s43066-023-00306-3.
  Article Google Scholar